Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · IEX Real-Time Price · USD
0.665
-0.068 (-9.25%)
At close: Apr 26, 2024, 4:00 PM
0.652
-0.013 (-1.96%)
After-hours: Apr 26, 2024, 4:39 PM EDT

Citius Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Oct - Sep.
Year 2023202220212020201920182017201620152013
Cash & Equivalents
26.5241.7570.1113.927.959.193.210.30.680.05
Cash & Cash Equivalents
26.5241.7570.1113.927.959.193.210.30.680.05
Cash Growth
-36.48%-40.45%403.79%75.03%-13.45%186.51%981.31%-56.15%1143.13%-
Receivables
000000.820000
Other Current Assets
7.852.812.70.07-0.010.060.220.60.060.05
Total Current Assets
34.3744.5672.8113.987.9410.063.420.890.740.1
Property, Plant & Equipment
0.460.650.830.99000000
Goodwill and Intangibles
9.359.359.359.359.351.591.591.590.010.01
Other Long-Term Assets
59.4459.4459.4419.4619.4619.419.419.4700
Total Long-Term Assets
69.2469.4469.6129.7928.820.9920.9921.060.010.01
Total Assets
103.61114142.4343.7736.7531.0524.4221.950.740.11
Accounts Payable
2.931.171.281.862.711.570.630.940.630.23
Current Debt
0.220.20.180.330.170.170.170.6700.95
Other Current Liabilities
2.633.172.531.911.721.441.673.570.750.15
Total Current Liabilities
5.784.533.984.14.613.182.475.181.381.32
Long-Term Debt
0.260.480.681.02000001.69
Other Long-Term Liabilities
6.145.564.994.994.9900000
Total Long-Term Liabilities
6.46.045.666.014.9900001.69
Total Liabilities
12.1810.579.6510.19.593.182.475.181.383.01
Total Debt
0.480.680.861.350.170.170.170.6702.64
Debt Growth
-29.04%-20.72%-36.73%681.65%---74.30%---
Retained Earnings
-162.23-129.69-96.05-70.59-53.05-40.26-27.72-17.34-9.04-5.4
Shareholders' Equity
90.83102.83132.1833.6727.1527.8721.9516.77-0.64-2.9
Net Cash / Debt
26.0441.0769.2612.567.789.013.03-0.380.68-2.58
Net Cash / Debt Growth
-36.60%-40.70%451.19%61.54%-13.71%197.14%----
Net Cash Per Share
0.170.280.640.320.390.840.55-0.100.32-2.18
Working Capital
28.5940.0368.839.883.336.880.96-4.29-0.64-1.22
Book Value Per Share
0.600.701.220.861.352.604.004.63-0.30-2.45
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).